Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ablynx and Algeta have entered into a research collaboration to evaluate the potential of novel alpha-pharmaceuticals, comprising Thorium-277, conjugated to tumour-targeting nanobodies.
Subscribe to our email newsletter
Under the collaboration, Ablynx will provide access to novel Nanobodies, generated using proprietary technology platform, and Algeta will provide access to chelation and conjugation technologies, as well as to its alpha-emitter thorium-227.
Algeta executive vice president and chief technology officer Thomas Ramdahl said the collaboration with Ablynx is designed to evaluate the potential of a Nanobody to act as the targeting molecule for the alpha-pharmaceutical payload, thorium-227.
"This payload has the potential to provide higher potency and more effective delivery over other therapeutic payloads, with the further advantage that there are no known cellular resistance mechanisms to the cell killing properties of alpha particles," Ramdahl added.
Ablynx chief scientific officer Andreas Menrad said the company is pleased to be working with Algeta to discover and develop novel cancer therapeutics based on both companies’ proprietary technologies.
"Our Nanobodies have the potential to selectively and efficiently deliver Algeta’s thorium-227 to the site of the tumour," Menrad added.
"We are very excited about combining our unique and powerful technology with Algeta’s leading payload expertise to search for breakthrough opportunities in oncology."